ClinicalTrials.gg
TerminatedNCT02146833SHIPUpdated Jan 26, 2023Results posted

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

A Phase 2 interventional study of Selinexor in Prostate Cancer, sponsored by Karyopharm Therapeutics Inc. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to enrollment challenges. The termination is not a consequence of any safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
2,250th of 3,023
20 · median 48
Started
2014
with 142 others
Phase 2
1,063 of 3,596
145 open now
Registered
1,620th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 2,250th largest by enrollment of the 3,023 interventional ones that give a count, is one of 143 that started in 2014, is one of 1,063 in phase 2, and was the 1,620th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Read the detailed description

This is a Phase 2, open-label study to explore the effect of selinexor (KPT-330) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Approximately 50 patients are planned for enrollment. Patients will receive an oral dose of selinexor on one of three dosing schedules.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • castrate-resistant prostate cancer
  • prostate cancer
  • Karyopharm
  • KPT-330
  • selinexor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the prostate with evidence for skeletal on bone scan and/or CT scan.
  • Must have received at least one agent known to impact survival (abiraterone, enzalutamide, etc.).
  • (ECOG) less than or equal to (≤ 2) or a Performance Status (KPS) ≥ 60%.
  • Serum testosterone levels less than (\<) 50 ng/ml.
  • Ongoing gonadal androgen deprivation therapy with luteinising hormone-releasing hormone (LHRH) analogues or orchiectomy. Participants, who have not had an orchiectomy, must be maintained on standard dosing of LHRH analogue therapy at appropriate frequency for the duration of the study.
  • Progression of disease despite androgen ablation shown by objective, documented evidence of disease progression (excluding prostate-specific antigen [PSA]), defined as one or both of the following:

    1. Soft tissue disease progression defined by (RECIST) version 1.1
    2. Bone disease progression defined by modified Prostate Cancer Clinical Trials Working Group 2 (PCWG2) with two or more new lesions or bone scan
  • Discontinuation of all prescribed to specifically treat prostate cancer (e.g., as a secondary hormonal manipulation) greater than (>) 4 weeks prior to receiving first dose of study drug. Glucocorticoids prescribed for a chronic non-cancer-related illness (e.g., asthma or [COPD]) that is well controlled with medical management are permissible to an equivalent of ≤ 10 milligrams (mg) prednisone daily.
  • Laboratory requirements:

    1. White blood cell (WBC) count > 3,000/microliter (μL)
    2. (ANC) > 1,500/μL
    3. ≥8.0 gram per deciliter (g/dL)
    4. count ≥150,000/μL
    5. Serum albumin ≥3.0 g/dL
    6. Calculated or measured > 30 milliliter per minute (mL/min)
  • A documenting prostate cancer in a target lesion (e.g., lymph node, bone lesion, or soft tissue lesion) within 3 months prior to study entry.
  • No evidence of chronic or acute disseminated intravascular coagulation or bleeding tendency.
  • Participant must be willing and able to comply with protocol requirements. All participants must sign an indicating that they are aware of the nature of this study.
  • Participant must be willing and able to sign an authorization for the release of their protected health information for study purposes.

Exclusion criteria

Exclusion Criteria:

  • Histologic variants other than adenocarcinoma in the primary tumor.
  • Participants who require or may be expected to require urgent treatment with docetaxel during the study (e.g., participants with visceral ).
  • Abnormal hepatic function:

    1. > 2 times the (2 x ULN) (except participants with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must not have a total bilirubin of > 3 x ULN)
    2. (AST) and alanine transaminase (ALT) > 2.5 x ULN (except participants with known liver involvement of their mCRPC who must not have an AST and ALT > 5 x ULN)
  • Therapy with other hormonal therapy, including any herbal product known to decrease PSA levels (e.g., Saw Palmetto and PC-SPES) within 4 weeks prior to receiving first dose of study drug.
  • Therapy with samarium-153, strontium-89, or radium-223 within 8 weeks prior to first dose of study drug.
  • Uncontrolled infection or concomitant illness that is not controlled with medical management.
  • Prior external beam radiation therapy completed \< 3 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug.
  • Any "currently active" second , other than non-melanoma skin cancer. Participants are not considered to have a "currently active" malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next 3 months.
  • Active psychiatric illnesses/social situations that would limit compliance with protocol requirements.
  • Active or uncontrolled disease that may require therapy during study.
  • Severely compromised immunological state, including known (HIV).
  • Known acute or chronic or C.
  • Chemotherapy and other therapies (targeted or immunotherapy) will require a 3-week before treatment initiation.
  • Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study treatment. Participants receiving ongoing bisphosphonate or denosumab therapy must have been on stable doses for at least 4 weeks prior to receiving first dose of study treatment. Participants on stable doses of bisphosphonates who show subsequent tumor progression may continue on this medication.
  • Impaired cardiac function or cardiac diseases, including any of the following:

    1. History or presence of serious uncontrolled ventricular arrhythmias or presence of uncontrolled atrial fibrillation.
    2. Clinically significant resting bradycardia (\< 50 beats per minute).
    3. Any of the following within 3 months prior to study entry: myocardial infarction severe/unstable angina, Coronary Artery Bypass Graft, Grade 3 or 4 Congestive Heart Failure, Cerebrovascular Accident, , or Pulmonary Embolism.
    4. Uncontrolled hypertension, as defined by a systolic blood pressure > 160 mm Hg and/or a diastolic blood pressure > 90 mm Hg with or without anti-hypertensive medication.
    5. Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring 2 or more interventions per month.
    6. Angina at rest.
  • Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a National Cancer Institute (NCI) (CTCAE), version 4.03 Grade of ≤ 1. Chemotherapy induced alopecia or Grade 2 neuropathy is allowed.
  • Any condition or situation, which in the Investigator's opinion, may put the participant at significant risk, confound the study results, or interfere significantly with the participant's participation in the study.
  • Men with a female partner of , (defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally for at least 12 consecutive months), who as a couple are unable or unwilling to employ two forms of highly effective (e.g., male condom with spermicide, diaphragm with spermicide, intra-uterine device). Two methods of contraception must be used by participants and their partners through the study and for 3 months after the end of study treatment.
  • (BMI) \< 1.2 m\^2, in order to prevent a participant from receiving a dose of selinexor > 70 mg/m\^2.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Selinexor Dosing Regimen 1

    80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)

    Drug: Selinexor

  • Experimental
    Selinexor Dosing Regimen 2

    80 mg once weekly for 4 weeks (4 doses per 28-day cycle)

    Drug: Selinexor

  • Experimental
    Selinexor Dosing Regimen 3

    60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)

    Drug: Selinexor

Interventions

  • Comparison of different dosages and dosing schedules of drug.

    Also known as: KPT-330

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Clinical Benefit Response (CBR)

    CBR was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) at 12 weeks as per the Response Evaluation Criteria in Solid Tumors (RECIST v.1.1; soft tissue lesions). CR: Disappearance of all target lesions. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taken as reference the baseline sum diameter. SD: steady state of disease; non-CR or non-PR or non-progressive disease.

    Time frame: At 12 weeks

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from first dose of study treatment until the disease progression or death due to any cause per RECIST v.1.1 criteria. If date of progression or death occurred after more than 1 missed study visit, participants were censored at the time of last radiologic assessment prior to the missed visit. Participants without documented progression were also censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.

    Time frame: From first dose of study treatment to time of disease progression or death, censored date (up to 23 months)

  2. Percentage of Participants With Best Overall Response: RECIST v1.1 Criteria

    Best overall response rate was defined as the percentage of participants who achieved best response of CR, PR as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taken as reference the baseline sum diameters.

    Time frame: From the date of first documented occurrence of response (CR or PR) until the date of documented progression or last disease assessment (up to 23 months)

  3. Absolute Values of Prostate Specific Antigen (PSA) Levels

    PSA marker was used for the assessment of disease progression and estimated the PSA level when compared to baseline.

    Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (each cycle of 28 days) and End of Treatment (30 days after last dose of study treatment)

  4. Percent Change From Baseline in Prostate Specific Antigen Levels

    PSA marker was used for the assessment of disease progression and estimated the PSA level when compared to baseline.

    Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (each cycle of 28 days) and End of Treatment (30 days after last dose of study treatment)

  5. Prostate Specific Antigen Response Rate

    PSA response rate was defined as number of participants who achieved a ≥30% drop in PSA at 12 Weeks when compared to baseline.

    Time frame: Baseline up to 12 weeks

  6. Overall Survival (OS)

    OS was defined as the time from first dose of study treatment until death due to any cause. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive.

    Time frame: From first dose of study treatment to death, censored date (up to 23 months)

  7. Pain Intensity Index (PPII) Total Score

    Quality of life (QoL) was assessed by verbal rating of participant's pain according to present pain intensity index. Participants were asked to describe "how severe their pain was at very moment". Present pain intensity was assessed on 5-point visual analog scale ranging from 0 to 5, where 0-no pain, 1-mild pain, 2-discomforting pain, 3-distressing pain, 4-horrible pain, and 5-excruciating pain. The higher scores indicated higher pain.

    Time frame: Baseline up to 30 days after last dose of study treatment (up to 23 months)

  8. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Events (TESAE)

    An adverse event (AE) was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. A serious adverse event (SAE) was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study.

    Time frame: From screening up to 23 months

07

Results

Posted Jan 26, 2021
Limitations and caveats
This study was terminated due to enrollment challenges. The termination was not a consequence of any safety concern.

Participant flow

This study was conducted at single center in United States of America from May 2014 to 01 April 2016. Due to early termination of study, participants in Arm 2 and 3 were not enrolled.

Participant flow — Overall Study
MilestoneArm 1: Selinexor
Started20
Completed9
Not completed11
Withdrew: Death10
Withdrew: No longer consented to study treatment1

Outcome measures

PrimaryPercentage of Participants With Overall Clinical Benefit Response (CBR)

CBR was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) at 12 weeks as per the Response Evaluation Criteria in Solid Tumors (RECIST v.1.1; soft tissue lesions). CR: Disappearance of all target lesions. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taken as reference the baseline sum diameter. SD: steady state of disease; non-CR or non-PR or non-progressive disease.

Time frame:
At 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Clinical Benefit Response (CBR)
Percentage of participantsArm 1: Selinexor
Percentage of Participants With Overall Clinical Benefit Response (CBR)25.0
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from first dose of study treatment until the disease progression or death due to any cause per RECIST v.1.1 criteria. If date of progression or death occurred after more than 1 missed study visit, participants were censored at the time of last radiologic assessment prior to the missed visit. Participants without documented progression were also censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.

Time frame:
From first dose of study treatment to time of disease progression or death, censored date (up to 23 months)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Best Overall Response: RECIST v1.1 Criteria

Best overall response rate was defined as the percentage of participants who achieved best response of CR, PR as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taken as reference the baseline sum diameters.

Time frame:
From the date of first documented occurrence of response (CR or PR) until the date of documented progression or last disease assessment (up to 23 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response: RECIST v1.1 Criteria
Percentage of participantsArm 1: Selinexor
Percentage of Participants With Best Overall Response: RECIST v1.1 Criteria0
SecondaryAbsolute Values of Prostate Specific Antigen (PSA) Levels

PSA marker was used for the assessment of disease progression and estimated the PSA level when compared to baseline.

Time frame:
Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (each cycle of 28 days) and End of Treatment (30 days after last dose of study treatment)
Reported as:
Mean · Microgram per liter (mcg/L)
Absolute Values of Prostate Specific Antigen (PSA) Levels
Microgram per liter (mcg/L)Arm 1: Selinexor
Baseline253.54 ± 380.796
Cycle 2 Day 11606.42 ± 5889.324
Cycle 3 Day 1204.64 ± 316.759
Cycle 4 Day 1160.50 ± 242.479
Cycle 5 Day 1199.70 ± 294.026
Cycle 6 Day 1253.95 ± 388.829
Cycle 7 Day 1264.40 ± 456.858
Cycle 8 Day 1417.93 ± 697.107
Cycle 9 Day 117.90 ± 24.607
Cycle 10 Day 11.30 ± NA
Cycle 11 Day 12.00 ± NA
End of Treatment1026.43 ± 2155.744
SecondaryPercent Change From Baseline in Prostate Specific Antigen Levels

PSA marker was used for the assessment of disease progression and estimated the PSA level when compared to baseline.

Time frame:
Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (each cycle of 28 days) and End of Treatment (30 days after last dose of study treatment)
Reported as:
Mean · percent change of PSA levels
Percent Change From Baseline in Prostate Specific Antigen Levels
percent change of PSA levelsArm 1: Selinexor
Cycle 2 Day 1210.74 ± 699.683
Cycle 3 Day 180.31 ± 90.723
Cycle 4 Day 130.51 ± 60.739
Cycle 5 Day 1187.86 ± 321.389
Cycle 6 Day 1281.05 ± 457.228
Cycle 7 Day 1327.46 ± 572.347
Cycle 8 Day 192.37 ± 167.366
Cycle 9 Day 11.43 ± 84.514
Cycle 10 Day 18.33 ± NA
Cycle 11 Day 166.67 ± NA
End of Treatment226.11 ± 200.131
SecondaryProstate Specific Antigen Response Rate

PSA response rate was defined as number of participants who achieved a ≥30% drop in PSA at 12 Weeks when compared to baseline.

Time frame:
Baseline up to 12 weeks
Reported as:
Count of participants · Participants
Prostate Specific Antigen Response Rate
ParticipantsArm 1: Selinexor
Prostate Specific Antigen Response Rate1
SecondaryOverall Survival (OS)

OS was defined as the time from first dose of study treatment until death due to any cause. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropout prior to study end, were censored at the day they were last known to be alive.

Time frame:
From first dose of study treatment to death, censored date (up to 23 months)

No measurements were reported for this outcome.

SecondaryPain Intensity Index (PPII) Total Score

Quality of life (QoL) was assessed by verbal rating of participant's pain according to present pain intensity index. Participants were asked to describe "how severe their pain was at very moment". Present pain intensity was assessed on 5-point visual analog scale ranging from 0 to 5, where 0-no pain, 1-mild pain, 2-discomforting pain, 3-distressing pain, 4-horrible pain, and 5-excruciating pain. The higher scores indicated higher pain.

Time frame:
Baseline up to 30 days after last dose of study treatment (up to 23 months)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Events (TESAE)

An adverse event (AE) was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. A serious adverse event (SAE) was defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study.

Time frame:
From screening up to 23 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Events (TESAE)
ParticipantsArm 1: Selinexor
At least one TEAE20
At least one TESAE9

Adverse events

Collected over From screening up to 23 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Selinexor10/20 (50%)9/20 (45%)20/20 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventArm 1: Selinexor
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/20
Cerebrovascular AccidentNervous system disorders2/20
HypoxiaRespiratory, thoracic and mediastinal disorders1/20
InfluenzaInfections and infestations1/20
Pneumonia Parainfluenzae ViralInfections and infestations1/20
ArthralgiaMusculoskeletal and connective tissue disorders1/20
MyalgiaMusculoskeletal and connective tissue disorders1/20
HemiparesisNervous system disorders1/20
PainGeneral disorders1/20
PyrexiaGeneral disorders1/20
Most frequent other events
Showing 10 of 88
Most frequent other events
EventArm 1: Selinexor
ThrombocytopeniaBlood and lymphatic system disorders16/20
FatigueGeneral disorders15/20
AnaemiaBlood and lymphatic system disorders12/20
LeukopeniaBlood and lymphatic system disorders11/20
NauseaGastrointestinal disorders11/20
HyperglycaemiaMetabolism and nutrition disorders10/20
LymphopeniaBlood and lymphatic system disorders9/20
Gamma-Glutamyltransferase IncreasedInvestigations8/20
Abnormal Loss Of WeightMetabolism and nutrition disorders7/20
Decreased AppetiteMetabolism and nutrition disorders7/20

Baseline characteristics

Safety population included all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Arm 1: Selinexor
Mean66.3 ± 9.62
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Selinexor
Female0
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Selinexor
Hispanic or Latino1
Not Hispanic or Latino19
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: Selinexor
Race — White17
Race — Black or African American1
Race — Asian1
Race — Native Hawaiian or Pacific Islander0
Race — American Indian or Alaska Native0
Race — Other1
Race — Unknown0
08

Study locations

1 site
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2021, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2014
First posted
May 26, 2014
Start
May 2014
Primary completionActual
Apr 1, 2016
CompletionActual
Apr 1, 2016
Results first posted
Jan 26, 2021
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02146833
Responsible party
Sponsor
First posted
May 26, 2014
Start date
May 2014
Primary completion
Apr 1, 2016
Completion
Apr 1, 2016
Results posted
Jan 26, 2021
Last update
Jan 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion